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The Staphylococcus aureus leukotoxin ED (LukED) is
a pore-forming toxin required for the lethality asso-
ciated with bacteremia in murine models. LukED
targets the chemokine receptor CCR5 to kill T lym-
phocytes, macrophages, and dendritic cells. LukED
also kills CCR5-deficient cells, like neutrophils, sug-
gesting the existence of additional cellular receptors.
Here, we identify the chemokine receptors CXCR1
and CXCR2 as the targets of LukED on neutrophils.
The LukE subunit binds neutrophils in a specific
and saturable manner, and this interaction is in-
hibited by CXCL8, the high-affinity endogenous
ligand of CXCR1 and CXCR2. LukED recognition of
CXCR1 and CXCR2 promotes the killing of mono-
cytes and neutrophils in vitro. LukED-mediated tar-
geting of CXCR1 and CXCR2+ cells contributes to
S. aureus pathogenesis and facilitates lethality in
systemically infectedmice. Thus, LukED is a versatile
toxin that endows S. aureus with the ability to simul-
taneously disarm both innate and adaptive compart-
ments of the host immune response.
INTRODUCTION
Staphylococcus aureus (S. aureus) is a Gram-positive bacterium
that is responsible for significant morbidity and mortality world-
wide (DeLeo and Chambers, 2009). The pathogenesis of this
organism depends on the production of an arsenal of virulence
factors that are thought to contribute to immune evasion and
subsequent manifestation of disease (Nizet, 2007; Otto, 2010;
Spaan et al., 2013b). Strains associated with human infection
can produce up to five different bicomponent leukotoxins
(LukSF-PV/PVL, HlgAB, HlgCB, LukED, and LukAB, also known
as LukHG) (Alonzo and Torres, 2013). These toxins potently
target and kill human neutrophils (polymorphonuclear cells;
PMNs), innate immune cells critical for defense against bacterial
infections (Rigby and DeLeo, 2012; Spaan et al., 2013b). For
many years, cellular targeting by the leukotoxins was thoughtCell Hostto be redundant. However, the recent identification of cellular
factors that facilitate their unique cellular tropism has proven
otherwise (Alonzo et al., 2013; DuMont et al., 2013a; Spaan
et al., 2013a).
CCR5 was recently identified as a LukED receptor on T cells,
macrophages, and dendritic cells (Alonzo et al., 2013), yet the
identification of this cellular target failed to explain how LukED
targets leukocytes that lack CCR5, which include PMNs. Here,
we report that LukED targets and kills CCR5-deficient leuko-
cytes via recognition of CXCR1 and CXCR2. We demonstrate
the importance of CXCR1 and CXCR2 targeting in vitro,
ex vivo, and in vivo, further highlighting the importance of LukED
to S. aureus pathogenesis.RESULTS
LukED Targets Monocytes and PMNs in a CCR5-
Independent Manner
While investigating the effects of LukED on primary human pe-
ripheral blood mononuclear cells (PBMCs), we observed that
monocytes within PBMCs isolated from a D32Ccr5 individual,
which naturally lacks CCR5 on the cell surface (Liu et al., 1996;
Samson et al., 1996), are targeted in a LukED-mediated,
CCR5-independent manner (Figure 1A). Similarly, monocytes
from PBMCs isolated from Ccr5+/+ individuals were susceptible
to LukED even in the presence of maraviroc, a CCR5 antagonist
known to block LukED-mediated killing of CCR5+ T cells (Fig-
ure S1A available online) (Alonzo et al., 2013). Moreover, we
found that primary human PMNs from Ccr5+/+ and D32Ccr5
donors were equally susceptible to LukED (Figures 1B and
S1B), indicating that LukED targets human monocytes and
PMNs in a CCR5-independent manner.
To evaluate the relevance of the CCR5-independent contribu-
tion of LukED to S. aureus virulence in vivo, we systemically in-
fected Ccr5+/+ and Ccr5/ mice with wild-type (WT) S. aureus,
an isogenic DlukED mutant, or an isogenic DlukED mutant con-
taining the lukED gene expressed from its native promoter inte-
grated in a single copy within the S. aureus chromosome
(DlukED::lukED) (Alonzo et al., 2012, 2013) and evaluated the
bacterial burden in infected livers 96 hr postinfection. DlukED-in-
fected Ccr5+/+ mice displayed a 2-log reduction in colony-form-
ing units (cfu) compared to those infected with WT or the& Microbe 14, 453–459, October 16, 2013 ª2013 Elsevier Inc. 453
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Figure 1. LukED Targets CXCR1 and CXCR2 to Kill Monocytes and
PMNs
(A) PBMCs isolated from a D32Ccr5 donor incubated with PBS or LukED
(75 nM) and gated for CD14 and CD3 positivity.
(B) Viability of primary human neutrophils (PMNs) isolated from a Ccr5+/+ or a
D32Ccr5 donor in the presence of LukE, LukD, or LukED (75 nM).
(C) Bacterial burden (cfu) from livers of Ccr5+/+ mice systemically infected with
isogenic S. aureus WT (n = 14), DlukED (n = 15), or DlukED::lukED (n = 15)
strains and Ccr5/ mice systemically infected with S. aureus WT (n = 10),
DlukED (n = 11), or DlukED::lukED (n = 3). **p < 0.01, ***p < 0.001, or ****p <
0.0001 by unpaired Student’s t test.
(D) Viability of transfected HEK293T cells incubated with LukED or LukSF-PV
(600 nM). Means ± SEM are shown (n = 3).
(E and F) CXCR1 and CXCR2 levels on the surface of PMNs (E) or monocytes
(F) as determined by flow cytometry.
(G) Viability of THP-1 cells transduced with nontarget or Cxcr2 shRNA treated
with LukED. Means ± SEM are shown (n = 3). See also Figure S1.
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LukED Kills Neutrophils via CXCR1 and CXCR2complementation strain (DlukED::lukED) (Figure 1C). Consistent
with prior studies, the bacterial burden in Ccr5/ mice infected
with WT S. aureus was reduced 1 log compared to Ccr5+/+
mice infected with WT S. aureus (Alonzo et al., 2013). Interest-
ingly, we observed that Ccr5/ mice infected with the DlukED
strain showed 3-log reduction in bacterial burden compared
to that of Ccr5/ mice infected with WT S. aureus, a pheno-
type fully complemented upon infection with DlukED::lukED
(Figure 1C).
LukED Targets CXCR1 and CXCR2 to Kill Leukocytes
The ex vivo experimentswithD32Ccr5 human leukocytes and the
in vivo experiments with Ccr5/ mice (Figures 1A–1C) suggest454 Cell Host & Microbe 14, 453–459, October 16, 2013 ª2013 Elsevthe existence of alternate LukED receptors on the surface of
PMNs and monocytes whose targeting contributes to establish-
ment of systemic S. aureus infection. To identify these targets,
a collection of chemokine receptors present on the surfaceof leu-
kocytes were ectopically expressed on human embryonic kidney
293T (HEK293T) cells followed by incubation with LukED. We
discovered that, as with CCR5, the chemokine receptors
CXCR1 or CXCR2, but not CXCR4, were sufficient to render
HEK293T cells susceptible to LukED, but not to the homologous
leukotoxin LukSF-PV (Figures1DandS1C),whichdoesnot target
CXCR2 (Spaan et al., 2013a). Consistent with their susceptibility
to LukED, the surface of themajority of primary humanPMNs and
peripheral bloodmonocytes are decoratedwith bothCXCR1 and
CXCR2 (Figures 1E and 1F). To determine if these receptors are
necessary to render host cells susceptible to LukED, a loss-of-
function approach was employed using lentiviral-based knock-
down and the human monocytic cell line THP-1, which displays
only CXCR2 (Figures S1D and S1E). We observed that Cxcr2
shRNA rendered THP-1 cells markedly resistant to LukED
compared to nontarget shRNA controls (Figure 1G). These data
demonstrate that CXCR1 and/or CXCR2 are necessary and suf-
ficient for LukED-mediated killing of mammalian cells.
LukE Specifically Binds to CXCR1 and CXCR2 on Host
Cells
Because of their primary role in defense against S. aureus (Rigby
and DeLeo, 2012), we focused the remainder of our studies on
LukED-mediated targeting of CXCR1 and CXCR2 on primary
PMNs. A binding assaywas employed in which PMNswere incu-
bated with GFP-fused LukE or LukD (GFP-LukE or GFP-LukD)
(Alonzo et al., 2013). Only GFP-LukE bound to PMNs in a
dose-dependent and saturable manner, while GFP-LukD dis-
played nonsaturable surface association (Figure 2A). GFP-
LukE binding was competed off with LukE, but not the equivalent
subunit of LukSF-PV, LukS-PV (Figure 2B), suggesting specific
interaction with CXCR1 and CXCR2.
The CXCR1 and CXCR2 receptors respond primarily to the
chemokine ligand CXCL8, which is produced by the host in
response to injury and infection (Stillie et al., 2009). In addition
to CXCL8, CXCR2 also responds to the chemokine CXCL1 (Stil-
lie et al., 2009). To test whether these chemokines are able to
inhibit LukED-mediated cytotoxicity, PMNs were treated with
LukED in the presence of either CXCL8 or CXCL1. CXCL8 pre-
vented LukED-mediated death of PMNs, but not CXCL1 (Fig-
ure 2C), suggesting that blockade of both receptors is required
to protect PMNs from LukED-mediated killing. CXCL8 protected
PMNs from LukED by preventing LukE binding to the cell surface
(Figure 2D), a prerequisite for cytotoxicity. While LukE and
CXCL8 both target CXCR1 and CXCR2, they do not appear to
engage the receptors to the same capacity, as LukE is unable
to elicit calcium mobilization upon incubation with PMNs (Fig-
ure S2). Consistent with the LukED-PMN binding studies, pull-
down experiments revealed that LukE, but not LukD, interacts
with both CXCR1 and CXCR2 (Figure 2E).
LukE Divergence Region 4 Is Required for LukED-
Mediated Killing of CXCR1 and CXCR2+ Cells
LukE and LukS-PV share71%amino acid identity (Figure S3A),
yet LukS-PV uses the C5a receptors (Spaan et al., 2013a)ier Inc.
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Figure 2. LukED Targets PMNs via LukE Binding to CXCR1 and
CXCR2
(A) Binding of GFP-LukE or GFP-LukD to the surface of PMNs evaluated by
flow cytometry. Means ± SEM are shown (n = 3).
(B) Binding of GFP-LukE (300 nM) to PMNs in the presence of unlabeled LukE
or LukS-PV as determined by flow cytometry. Means ± SEM are shown (n = 3).
(C) Viability of PMNs challenged with a lethal dose of LukED (75 nM) in the
presence of CXCL8 or CXCL1. Means ± SEM are shown (n = 3).
(D) Binding of GFP-LukE (300 nM) to the surface of PMNs in the presence of
CXCL8. Means ± SEM are shown (n = 3).
(E) Interaction of His-LukE or His-LukD with cell lysates containing hemag-
glutinin (HA)-tagged CXCR1 or CXCR2. Immunoblots are representative of at
least three independent experiments. See also Figure S2.
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LukED Kills Neutrophils via CXCR1 and CXCR2instead ofCXCR1andCXCR2 to target humanPMNs (Figure 1D).
Amino acid sequence alignment of LukE and LukS-PV revealed
five regions containing significant sequence divergence (diver-
gence regions 1–5, DR1–DR5) (Figure S3A). These DRs are
located in the rim domain of the LukE and LukS-PV structures
(Figures 3A and 3B), which has been hypothesized to play a
role in receptor recognition (Guillet et al., 2004; Olson et al.,
1999; Pe´delacq et al., 1999). We generated hybrid LukE/S-PV
toxins to test whether any of these five DRs are involved in
conferring specificity of LukE toward human PMNs. The LukE/
S-PV hybrid proteins were purified, mixed at an equimolar ratio
with LukD, and incubated with PMNs to evaluate their activity.
We found that only the LukEDR4D and LukEDR5D toxins wereCell Hostimpaired in cytotoxic activity toward PMNs compared to WT
LukED (Figures 3C and S3B).
To evaluate whether the lack of cytotoxicity exhibited by the
LukEDR4D and LukEDR5D hybrids was specific toward CXCR1
and CXCR2+ cells, we also tested their activity toward a
CCR5+ T cell line (Alonzo et al., 2013). We observed that
LukEDR5D was also impaired in killing CCR5+ cells, suggesting
that LukE’s DR5 is required for toxin activity rather than receptor
targeting (Figures 3C, 3D, S3B, and S3C). Remarkably,
LukEDR4Dwas able to target CCR5+ cell lines and primary human
T cells at a potency similar to that ofWT LukED (Figures 3D, S3C,
and S3D). Further analysis of PBMCs revealed that LukED also
targets a subset of CD8+ T cells and primary humanCXCR1+ nat-
ural killer (NK) cells in a DR4-dependent manner (Figure S3D).
LukE DR4 was also required for LukED-mediated killing of pri-
mary human monocytes despite also displaying CCR5 on their
surfaces (Figure S3D). These data demonstrate that CXCR1
and CXCR2 are likely the preferred receptors for LukED-medi-
ated targeting of monocytes, a finding consistent with the sus-
ceptibility of D32Ccr5 monocytes to LukED (Figure 1A).
We found that in contrast to LukE, LukEDR4 was unable to
compete with GFP-LukE for binding to the plasma membrane
of PMNs, establishing the role of the DR4 domain in recognition
of CXCR1 and CXCR2+ cells (Figure 3E). The 15 amino acid
sequence of LukE’s DR4, residues 182–196 of the mature pro-
tein, forms a loop containing two glycine residues (G186 and
G189) and two proline residues (P184 and P187) that present a
polar surface sufficiently distinct from that of LukS-PV’s DR4,
which likely determines the tropism of LukE toward CXCR1
and CXCR2.
We next investigated the contribution of CXCR1 and CXCR2
targeting by LukED to S. aureus-mediated killing of PMNs during
ex vivo infection. Since S. aureus produces an array of toxins
capable of killing PMNs (Alonzo and Torres, 2013) and LukED
is produced at sublytic quantities by S. aureus in broth culture
(Alonzo et al., 2012; Dumont et al., 2011), we opted to use an en-
gineered S. aureus strain lacking all of the pore-forming toxins
(hla, lukAB, hlgACB, and lukED) where the lukED or lukEDR4D
loci were expressed in trans from a plasmid using the lukAB pro-
moter (Figure S4A). As expected, the toxinless S. aureus strain
was impaired in killing PMNs, whereas the strain complemented
in trans with lukED was able to kill these cells (Figure 3G). The
cytotoxic activity of the LukED-producing S. aureus strain was
inhibited by CXCL8 and required LukE’s DR4 domain, as the
LukEDR4D-producing strain exhibited reduced PMN killing
compared to theWT LukED-producing strain (Figure 3G). Impor-
tantly, the defect in cell killing exhibited by the LukEDR4D-pro-
ducing strain was specific toward CXCR1 and CXCR2+ cells,
as LukEDR4D-producing strains retained the ability to kill
CCR5+ cells (Figure 3H).
To evaluate if LukED also kills murine leukocytes in a CXCR1-
and CXCR2-dependent manner, murine peritoneal exudate cells
(PECs) were treated with LukED or LukEDR4D.While LukED killed
79% of the PMNs, LukEDR4D was significantly impaired and
only killed 8% of these cells. In contrast to the effects on
PMNs, CCR5+ macrophages from within the PEC population
were equally susceptible to both LukED and LukEDR4D (Figures
4A and S4B), consistent with the finding that LukED kills these
cells in a strictly CCR5-dependent manner (Alonzo et al.,& Microbe 14, 453–459, October 16, 2013 ª2013 Elsevier Inc. 455
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Figure 3. LukE Amino Acids 182–196 in
Divergence Region 4 Are Required for
LukED Targeting of CXCR1 and CXCR2+
Cells
(A) The structures of LukE and LukS-PV differ pri-
marily in the rim domain surface as indicated by a
color ramp in which highly divergent residues are
colored in dark blue, identical residues are colored
in red, and conservative substitutions have an in-
termediate color.
(B) LukE (3ROH, light blue) and LukS (1T5R, light
green) structural alignment with DR1–DR5 amino
acids highlighted as follows: DR1 (yellow, 57–75),
DR2 (gray, 140–150), DR3 (orange, 164–178), DR4
(blue, 182–196), and DR5 (red, 237–271).
(C) Viability of PMNs treated with WT and LukEDR
hybrids (DR1–DR5, 300 nM). Insert is a Coomassie
blue-stained gel of purified LukEDR hybrids.
Means ± SEM are shown (n = 9).
(D) Viability of CCR5+ cells treated with the indi-
cated toxins (300 nM). Means ± SEM are shown
(n = 3). Data shown are representative of one out of
three experiments done in triplicate. **p % 0.001
and ***p % 0.0001 by one-way ANOVA with Tu-
key’s multiple comparison test.
(E) Binding of GFP-LukE (300 nM) in the presence
of unlabeled LukE or LukEDR4 as determined by
flow cytometry. Means ± SEM are shown (n = 3).
(F) LukEDR4 (blue) structure with residues that differ
between LukE and LukS-PV depicted as sticks.
(G and H) Ex vivo infection of PMNs (G) or HUT-R5
(H) with S. aureus Newman DDDD (DlukED,
DhlgACB::tet, DlukAB::spec, Dhla::ermC) strains
containing the pOS1-PlukAB-lukA
ss-63His vector
either empty (empty) or with lukED or lukEDR4D at a
multiplicity of infection of 10. Data shown are
representative of one out of three experiments
done in triplicate. *p < 0.05; ***p% 0.0001 by one-
way ANOVA (G). See also Figure S3 and Table S3.
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LukED Kills Neutrophils via CXCR1 and CXCR22013). We also assessed the viability of PMNs from tissues in-
fected with an S. aureus Newman DlukED deletion mutant or a
DlukED mutant complemented with a single chromosomal
copy of either the WT lukED (Alonzo et al., 2012) or the lukEDR4D
operon with expression driven by the endogenous lukED
promoter (DlukED, DlukED::lukED, or DlukED::lukEDR4D, respec-
tively). Importantly, the DlukED::lukED and DlukED::lukEDR4D
isogenic strains produced similar levels of toxin in vitro (Fig-
ure S4C). We observed that PMNs isolated from S. aureus
DlukED- or DlukED::lukEDR4D-infected mice were largely
protected from toxin-mediated death compared to that of
DlukED::lukED-infected mice (Figures 4B and S4D), demon-
strating that the DR4 domain is required for LukED-mediated
PMN targeting in vivo.
LukED Targeting of CXCR1 and CXCR2 Contributes to
S. aureus Pathogenesis
LukED contributes to the mortality observed in mice infected
systemically with S. aureus, including methicillin-resistant
S. aureus (MRSA) (Alonzo et al., 2012, 2013). To evaluate the
role of LukED-mediated targeting of CXCR1 and CXCR2 in
conferring this phenotype, we monitored the survival of mice in-456 Cell Host & Microbe 14, 453–459, October 16, 2013 ª2013 Elsevfected systemically with isogenic S. aureus DlukED,
DlukED::lukED, or DlukED::lukEDR4D strains described above.
As expected (Alonzo et al., 2012, 2013), mice infected with the
DlukED strain survived the infection, while mice infected with
theDlukED::lukED-complemented strain succumbed to infection
(Figure 4C). In contrast, we observed that the DlukED::lukEDR4D-
infected mice were markedly protected compared to the
DlukED::lukED-complemented strain (Figure 4C). Altogether,
these findings demonstrate that LukED-mediated targeting of
CXCR1 or CXCR2 promotes S. aureus pathogenesis in vivo.
DISCUSSION
The identification of the chemokine receptors CXCR1 and
CXCR2 as LukED targets provides an explanation for the ability
of this toxin to kill immune cells that lack CCR5, substantiates
previous studies demonstrating PMN targeting in vitro by LukED,
and directly links PMN cytotoxicity by a leukotoxin to S. aureus
pathogenesis in vivo. It is well established that purified
S. aureus bicomponent leukotoxins (LukSF-PV/PVL, HlgAB,
HlgCB, LukED, and LukAB) kill PMNs in vitro. As such, they
have been presumed to play strictly redundant roles duringier Inc.
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Figure 4. LukED-Mediated Killing of CXCR1 and CXCR2+ Cells Con-
tributes to S. aureus Pathogenesis in Mouse Models of Systemic
Infection
(A) Viability of peritoneal elicited murine PMNs (CXCR2+) or macrophages
(CCR5+) in the presence of PBS (No Toxin), LukED, or LukEDR4D (300 nM).
FACS plots are representative of one of three mice per treatment.
(B) Murine PMNs isolated from the liver (top panel) and kidneys (bottom panel)
of mice systemically infected with isogenic S. aureus Newman DlukED,
DlukED::lukED, or DlukED::lukEDR4D strains. FACS plots are representative of
one of ten infected mice per strain.
(C) Survival of mice infected with isogenic S. aureus DlukED (n = 10),
DlukED::lukED (+lukED; n = 16), or DlukED::lukEDR4D (+lukEDR4D; n = 16)
strains. Statistical analysis for DlukED versus +lukED, ****p = 0.0001; DlukED
versus +lukEDR4D, p = 0.0577; and +lukED versus +lukEDR4D, ***p = 0.0003 by
log-rank (Mantel-Cox test). See also Figure S4.
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Cell HostS. aureus infection. However, demonstrating toxin redundancy
(or lack thereof) using in vivo models has proven difficult. For
example, LukSF-PV/PVL and LukAB target cells in a species-
specific manner (DuMont et al., 2013a; Spaan et al., 2013a),
limiting the implementation of murine models to study their
mechanism of action. In contrast, the broad host range and spe-
cific cellular targets (CCR5, CXCR1, and CXCR2) of LukED allow
detailed in vivo mechanistic studies of toxin-mediated pathobi-
ology via leukocyte targeting. Thus, through the study of LukED,
we can now begin tomodel leukotoxin activity in vivo using small
animal infection models.
Support for a nonredundant in vivo mechanism of action of the
leukotoxins is provided by recent studies that suggest that not all
leukotoxins are produced by S. aureus simultaneously or at
equal levels (DuMont et al., 2013b). For example, LukSF-PV/
PVL and LukAB are produced in a manner that depends on spe-
cific growth conditions (DuMont et al., 2013b), while LukED is
produced only at low levels using similar conditions (Alonzo
et al., 2012; DuMont et al., 2013b). We suspect that in an animal
model in which the host is fully sensitive to each leukotoxin, a
model currently unavailable at this time, a profound effect on
S. aureus pathogenesis would be seen due to combined toxin
targeting of PMNs and toxin-specific targeting of other leuko-
cytes dictated by environmental conditions, as well as the recep-
tor profiles of specific immune cell targets. Importantly, the
recent identification of unique leukotoxin receptors for LukED,
LukSF-PV/PVL, and LukAB implies that although each toxin
can target PMNs, they do so in a nonredundant manner (Alonzo
et al., 2013; DuMont et al., 2013a; Spaan et al., 2013a).
Since PMNs are the first responders to infection, and defects
in PMN function result in extraordinary susceptibility to S. aureus
infection (Rigby and DeLeo, 2012), it is logical that a pathogen
like S. aureuswould produce virulence factors such as leukotox-
ins to kill these cells (Alonzo and Torres, 2013; Spaan et al.,
2013b). Nevertheless, the sustained function of PMNs is also
dependent on their continuous recruitment and enhanced po-
tency or lifespan through inflammatory mediators secreted at
the site of infection (Cho et al., 2010; Kolaczkowska and Kubes,
2013; Lin et al., 2009). Indeed, quantitative and qualitative
disruption of either PMNs or T cells, especially effector subsets
that secrete interleukin-17 (IL-17) or interferon-gamma (IFNg),
greatly increase the susceptibility to S. aureus infection (Alonzo
et al., 2012, 2013; Cho et al., 2010; Lin et al., 2009). As such,
through the use of CXCR1 and CXCR2, LukED targets largely
innate defenses mediated by PMNs, monocytes, and NK cells,
whereas by targeting CCR5+ cells, LukED eliminates T cell sub-
sets including memory cells, Th1 cells, and Th17 cells as well as
professional antigen-presenting cells (Alonzo et al., 2013), all of
which are critical in anti-Staph immunity.
Due to the temporal nature of the host immune response and
the diverse cell types involved in infection resolution, we
observed that blockade of LukED targeting of either CXCR1,
CXCR2, or CCR5 (Alonzo et al., 2013) leads to enhanced surviv-
ability in vivo in amurine model of systemic infection. These find-
ings support a role for toxin-mediated PMN killing as an efficient
immune evasion mechanism that ultimately facilitates pathogen-
esis. Importantly, we cannot exclude other roles for LukED, as
they relate to animal death at this time. It is, however, well estab-
lished that antibody-mediated depletion of PMNs in systemic& Microbe 14, 453–459, October 16, 2013 ª2013 Elsevier Inc. 457
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mediated death (Alonzo et al., 2012; Corbin et al., 2008; Gre-
sham et al., 2000). Thus, we suggest that S. aureus produces
LukED to function in a similar manner, as a suppressor of the
host’s ability to contain infection by eliminating leukocytes
involved in infection control and resolution.
EXPERIMENTAL PROCEDURES
Ethics Statement
All experiments involving animals were reviewed and approved by the Institu-
tional Animal Care andUse Committee of NewYork University. All experiments
were performed according to NIH guidelines, the Animal Welfare Act, and US
Federal law.
Blood was obtained from de-identified, consenting, healthy adult donors as
buffy coats from the New York Blood Center.
Binding and Competition Assays
For binding assays, a dose response of GFP-LukE or GFP-LukD was added to
53 104 human PMNs and incubated for 30min on ice. Then cells were washed
once in fluorescence-activated cell sorting (FACS) buffer (PBS + 2% fetal
bovine serum (FBS) + 0.05% sodium azide) and fixed for 15 min at room tem-
perature, followed by flow cytometric analysis. Mean fluorescence intensity
(MFI) of GFP+ cells wasmeasured to establish the toxin concentration required
to achieve saturable binding. For the remaining competition assays, a dose
response of either LukE or LukS-PV was coincubated with a constant satu-
rable concentration of LukE-GFP (300 nM) for 30 min. Cells were washed
once in FACS buffer, fixed for 15 min in FACS fixation buffer (FACS buffer +
2% paraformaldehyde + 0.05% sodium azide), washed again in FACS buffer,
and binding was assessed by flow cytometry. The mean GFP fluorescence in-
tensity is represented as percent GFP+, based on the maximal fluorescence
observed upon incubation with 300 nMGFP-LukE. For competition assays us-
ing CXCL8 or CXCL1, a dose response of either chemokine was added to hu-
man PMNs for 30 min on ice, followed by addition of 300 nM GFP-LukE. Cells
were washed once in FACS buffer, fixed for 15 min in FACS fixing buffer,
washed again in FACS buffer, and binding was assessed by flow cytometry
as described above. Results for these assays were depicted graphically using
GraphPad Prism software (version 5.0f).
Ex Vivo Infection Experiments
S. aureus Newman DDDD strains lacking all four pore-forming toxins (DlukED
Dhla::ermC DhlgACB::tet DlukAB::spec) containing the pOS1-PlukAB-lukA
ss-
63His vector construct with either empty vector (empty), lukED, or lukEDR4D
(Tables S1 and S2) were subcultured for 4.5 hr, followed by normalization to
1 3 109 cfu per ml in RPMI + 10% FBS. Cells were then diluted 1:10, and
20 ml was added to 80 ml of media containing 2 3 105 PMNs seeded into 96-
well plates. Infections were carried out for 3.5 hr at 37C with shaking at
180 rpm. Lysostaphin (2 mg ml1) was added for 20 min at 37C with shaking
at 180 rpm to kill all bacteria. Cells were centrifuged for 5 min at 1,500 rpm and
4C, followed by fixing in FACS fixation buffer. To analyze toxin-mediated
killing by flow cytometry, cellular depletion from gated live cells was evaluated.
Percent of cell death was calculated by comparing cells remaining in the live
gate to that of Newman DDDD strain containing the pOS1-PlukAB modified
empty vector (no toxin), which was set to 0% dead.
Generation of S. aureus Chromosomal Integration Strains
For complementation with WT LukED, the entire lukED locus was amplified
from S. aureus Newman genomic DNA using the primers VJT605 and
VJT299 (Table S3), and chromosomal integration was performed as described
(Alonzo et al., 2012).
To generate the lukEDR4D integration construct, the lukED promoter region
was amplified from S. aureus Newman genomic DNA using primers VJT605
and VJT1019. The lukEDR4 coding region was amplified using purified plasmid
from strain VJT34.58 containing lukEDR4 with primers VJT1020 and VJT1021.
S. aureus Newman genomic DNA was used to amplify lukD and the intergenic
region between lukE and lukD using primers VJT1022 and VJT299. A final over-
lap PCR reaction was performedwith the resultant DNA fragments and primers458 Cell Host & Microbe 14, 453–459, October 16, 2013 ª2013 ElsevVJT605 and VJT299. The lukED and lukEDR4D constructs were transformed
into E. coli DH5a, and clones were selected by ampicillin resistance. The pu-
rified plasmids were cloned into pJC1112 using BamHI and PstI restriction
sites and transformed into DH5a. The resulting recombinant plasmids were
introduced by electroporation into strain RN9011, containing plasmid
pRN7023, which encodes the SaPI1 integrase to facilitate single-copy chro-
mosomal integration into the S. aureus SaPI1 site (Ruzin et al., 2001), and
selected for chloramphenicol and erythromycin resistance, as previously
described (Alonzo et al., 2012). The SaPI1 integrated constructs were then
transduced into strain VJT8.16 (Newman DlukED), using previously described
methods (Alonzo et al., 2012).
To generate an empty vector-containing DlukED strain, the pJC1112 vector
was electroporated into RN9011 as above. Bacteriophage-mediated trans-
duction was then used to introduce the integrated complementation vector
into S. aureus strain Newman DlukED using previously described methods
(Alonzo et al., 2012).
Murine In Vitro and In Vivo Experiments
To evaluate LukED-mediated killing of murine cells in vitro, C57BL/6 WT mice
(Taconic) were injected intraperitoneally with 1 3 107 cfu of heat-killed
S. aureus Newman DlukED. At 24 hr postinjection, another dose of 1 3 107
cfu of heat-killed S. aureus Newman DlukED was injected as before. After an
additional 24 hr, mice were sacrificed, and S. aureus-elicited immune cells
were collected by peritoneal cavity lavage using 8 ml of PBS. Red blood cells
were lysed using 2ml ACK lysis buffer (Gibco), followed by resuspension of re-
maining peritoneal exudate cells in RPMI + 10% FBS. Cells were incubated
with PBS, LukED, or LukEDR4D (300 nM) and incubated for 30 min on ice. After
incubation, the cells were washed three times with PBS and then stained with
the fixable viability dye eFluor 450, followed by cell surface staining with
CD11b, B220, F480, CD3, Ly6G, CCR5, and CXCR2 antibodies. Cell viability
of specific immune cell populations was subsequently analyzed on an LSR II
flow cytometer. FACS plots are representative of results obtained from cells
isolated from at least three independently infected mice. Cell death was quan-
tified and displayed graphically as the percentage of eFluor 450+ cells.
For in vivo experiments, 8-week-old female C57BL/6 mice (Taconic) were
anesthetized with 250 ml of Avertin (2,2,2-tribromoethanol dissolved in tert-
Amyl-alcohol and diluted to a final concentration of 2.5% v/v in sterile saline),
followed by retro-orbital injection of 13 107 cfu of isogenic S. aureus Newman
strains containing a lukED deletion complemented in single copy with either
the empty vector pJC1112 (DlukED) or WT lukED or lukEDR4D loci
(DlukED::lukED and DlukED::lukEDR4D, respectively) in the SaPI1 site of
S. aureus (Alonzo et al., 2012), resulting in single-copy chromosomal comple-
mentation of lukED or lukEDR4D with endogenous gene expression driven by
the native lukED promoter. At 96 hr postinfection, mice were sacrificed and
organs were harvested and homogenized to evaluate the bacterial burden
(cfu). To determine the effects of infection with these strains on immune cells,
organ immune cell suspensions were purified using a 40%/80% Percoll (GE
Healthcare) density gradient centrifugation and subsequently processed and
stained as described before (Alonzo et al., 2013). Cell viability of specific
immune cell populations was determined by flow cytometric analysis on an
LSR II flow cytometer. FACS plots are representative of results obtained
from at least nine infected animals per group. Cell death was quantified and
displayed graphically as the percentage of eFluor 450+ cells.
For survival experiments, 3 hr subcultures of isogenicS. aureus strains New-
man DlukED, DlukED::lukED, and DlukED::lukEDR4D described above were
normalized to 5 3 108 cfu per ml using PBS. Female ND4 mice (5–6 weeks
old; Harlan) were anesthetized intraperitoneally with 250 ml of Avertin, followed
by retro-orbital injection of 100 ml of normalized bacteria, for a final cfu count of
53 107. Survival of micewasmonitored over time until signs ofmorbidity, such
as hunched posture, ruffled fur, weight loss, inability to acquire food or water,
ataxia, and hindlimb paralysis were reached, at which point the mice were
immediately sacrificed, and survival curves were plotted over time (hr).
Structural Modeling of LukE/LukS-PV Structural Diversity
The LukE and LukS-PV amino acid sequences were aligned with ClustalW and
scored with a Risler matrix according to the extent of sequence variation using
ESPript. Scores were displayed on the LukE structure surface with a color
ramp (red, orange, yellow, green, light blue, dark blue) in which strictlyier Inc.
Cell Host & Microbe
LukED Kills Neutrophils via CXCR1 and CXCR2conserved residues are colored red and the most divergent residues are
colored dark blue. Conservative substitutions are represented by intermediate
colors. All structural figures were prepared using PyMOL.
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